Physiological and pathophysiological characteristics of ataxin-3 isoforms
暂无分享,去创建一个
O. Riess | C. Gloeckner | T. Schmidt | Felix von Zweydorf | C. Ruess | S. Dold | J. Schmidt | J. Schneider | Barbara Peixoto Pinheiro | Daniel Weishäupl | Thorsten Schmidt
[1] R. Krüger,et al. Mitochondrial Morphology, Function and Homeostasis Are Impaired by Expression of an N-terminal Calpain Cleavage Fragment of Ataxin-3 , 2018, Front. Mol. Neurosci..
[2] I. M. Martins,et al. Karyopherin α-3 is a key protein in the pathogenesis of spinocerebellar ataxia type 3 controlling the nuclear localization of ataxin-3 , 2018, Proceedings of the National Academy of Sciences.
[3] R. Hartmann-Petersen,et al. Polyglutamine expansion of ataxin-3 alters its degree of ubiquitination and phosphorylation at specific sites , 2017, Neurochemistry International.
[4] C. Carlson,et al. A combinatorial approach to identify calpain cleavage sites in the Machado-Joseph disease protein ataxin-3 , 2017, Brain : a journal of neurology.
[5] H. Paulson,et al. Interaction of the polyglutamine protein ataxin-3 with Rad23 regulates toxicity in Drosophila models of Spinocerebellar Ataxia Type 3 , 2017, Human molecular genetics.
[6] Kara Dolinski,et al. The BioGRID interaction database: 2017 update , 2016, Nucleic Acids Res..
[7] Marco Y. Hein,et al. The Perseus computational platform for comprehensive analysis of (prote)omics data , 2016, Nature Methods.
[8] S. Gygi,et al. mTOR inhibition activates overall protein degradation by the ubiquitin proteasome system as well as by autophagy , 2015, Proceedings of the National Academy of Sciences.
[9] Sokol V. Todi,et al. The deubiquitinase ataxin-3 requires Rad23 and DnaJ-1 for its neuroprotective role in Drosophila melanogaster , 2015, Neurobiology of Disease.
[10] H. Paulson,et al. A knockin mouse model of spinocerebellar ataxia type 3 exhibits prominent aggregate pathology and aberrant splicing of the disease gene transcript. , 2015, Human molecular genetics.
[11] Karolina A Majorek,et al. Double trouble—Buffer selection and His‐tag presence may be responsible for nonreproducibility of biomedical experiments , 2014, Protein science : a publication of the Protein Society.
[12] Sokol V. Todi,et al. Using membrane‐targeted green fluorescent protein to monitor neurotoxic protein‐dependent degeneration of Drosophila eyes , 2014, Journal of neuroscience research.
[13] K. Scaglione,et al. Ubiquitin-Binding Site 2 of ataxin-3 prevents its proteasomal degradation by interacting with Rad23 , 2014, Nature Communications.
[14] N. Mizushima,et al. Cycloheximide inhibits starvation-induced autophagy through mTORC1 activation. , 2014, Biochemical and biophysical research communications.
[15] K. Scaglione,et al. Ubiquitination Regulates the Neuroprotective Function of the Deubiquitinase Ataxin-3 in Vivo* , 2013, The Journal of Biological Chemistry.
[16] R. Montiel,et al. Transcript Diversity of Machado–Joseph Disease Gene (ATXN3) Is Not Directly Determined by SNPs in Exonic or Flanking Intronic Regions , 2013, Journal of Molecular Neuroscience.
[17] Duhee Bang,et al. A library of TAL effector nucleases spanning the human genome , 2013, Nature Biotechnology.
[18] C. Richter,et al. Calpain-mediated ataxin-3 cleavage in the molecular pathogenesis of spinocerebellar ataxia type 3 (SCA3). , 2013, Human molecular genetics.
[19] K. Xia,et al. SUMO-1 Modification on K166 of PolyQ-Expanded aTaxin-3 Strengthens Its Stability and Increases Its Cytotoxicity , 2013, PloS one.
[20] Beatriz Alvarez-Castelao,et al. A Critical Appraisal of Quantitative Studies of Protein Degradation in the Framework of Cellular Proteostasis , 2012, Biochemistry research international.
[21] Andrei L. Turinsky,et al. A Census of Human Soluble Protein Complexes , 2012, Cell.
[22] H. Paulson,et al. Toward understanding Machado–Joseph disease , 2012, Progress in Neurobiology.
[23] J. D. Mills,et al. Alternative splicing of mRNA in the molecular pathology of neurodegenerative diseases , 2012, Neurobiology of Aging.
[24] J. Mertens,et al. Excitation-induced ataxin-3 aggregation in neurons from patients with Machado–Joseph disease , 2011, Nature.
[25] Jin-Soo Kim,et al. Surrogate reporters for enrichment of cells with nuclease-induced mutations , 2011, Nature Methods.
[26] C. Crochemore,et al. Induction of autophagy with catalytic mTOR inhibitors reduces huntingtin aggregates in a neuronal cell model , 2011, Journal of neurochemistry.
[27] K. Riabowol,et al. REAP: A two minute cell fractionation method , 2010, BMC Research Notes.
[28] H. Paulson,et al. Splice Isoforms of the Polyglutamine Disease Protein Ataxin-3 Exhibit Similar Enzymatic yet Different Aggregation Properties , 2010, PloS one.
[29] R. Montiel,et al. The (CAG)n tract of Machado–Joseph Disease gene (ATXN3): a comparison between DNA and mRNA in patients and controls , 2010, European Journal of Human Genetics.
[30] R. Montiel,et al. Increased transcript diversity: novel splicing variants of Machado–Joseph Disease gene (ATXN3) , 2010, neurogenetics.
[31] O. Riess,et al. Polyglutamine-induced neurodegeneration in SCA3 is not mitigated by non-expanded ataxin-3: Conclusions from double-transgenic mouse models , 2010, Neurobiology of Disease.
[32] Wolfgang Huber,et al. EBImage—an R package for image processing with applications to cellular phenotypes , 2010, Bioinform..
[33] Hartwig Wolburg,et al. Reversibility of symptoms in a conditional mouse model of spinocerebellar ataxia type 3. , 2009, Human molecular genetics.
[34] O. Riess,et al. Identification and functional dissection of localization signals within ataxin-3 , 2009, Neurobiology of Disease.
[35] B. Evert,et al. CK2-dependent phosphorylation determines cellular localization and stability of ataxin-3. , 2009, Human molecular genetics.
[36] H. Paulson,et al. Ubiquitination directly enhances activity of the deubiquitinating enzyme ataxin‐3 , 2009, The EMBO journal.
[37] H. Paulson,et al. The Deubiquitinating Enzyme Ataxin-3, a Polyglutamine Disease Protein, Edits Lys63 Linkages in Mixed Linkage Ubiquitin Chains* , 2008, Journal of Biological Chemistry.
[38] D. Timmann,et al. Early symptoms in spinocerebellar ataxia type 1, 2, 3, and 6 , 2008, Movement disorders : official journal of the Movement Disorder Society.
[39] M. Valtorta,et al. Study of subcellular localization and proteolysis of ataxin-3 , 2008, Neurobiology of Disease.
[40] Janghoo Lim,et al. Opposing effects of polyglutamine expansion on native protein complexes contribute to SCA1 , 2008, Nature.
[41] R. Roepman,et al. A novel tandem affinity purification strategy for the efficient isolation and characterisation of native protein complexes , 2007, Proteomics.
[42] T. Klockgether,et al. Inactivation of the mouse Atxn3 (ataxin-3) gene increases protein ubiquitination. , 2007, Biochemical and biophysical research communications.
[43] H. Paulson,et al. Cellular Turnover of the Polyglutamine Disease Protein Ataxin-3 Is Regulated by Its Catalytic Activity* , 2007, Journal of Biological Chemistry.
[44] P. Breuer,et al. Josephin domain-containing proteins from a variety of species are active de-ubiquitination enzymes , 2007, Biological chemistry.
[45] L. Rüttiger,et al. Nuclear Localization of Ataxin-3 Is Required for the Manifestation of Symptoms in SCA3: In Vivo Evidence , 2007, The Journal of Neuroscience.
[46] G. Lederkremer,et al. Transient arrest in proteasomal degradation during inhibition of translation in the unfolded protein response. , 2007, The Biochemical journal.
[47] Tao Zhang,et al. p45, an ATPase subunit of the 19S proteasome, targets the polyglutamine disease protein ataxin‐3 to the proteasome , 2007, Journal of neurochemistry.
[48] D. Geschwind,et al. Functional genomics and biochemical characterization of the C. elegans orthologue of the Machado‐Joseph disease protein ataxin‐3 , 2007, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[49] T. Klockgether,et al. Ataxin-3 Represses Transcription via Chromatin Binding, Interaction with Histone Deacetylase 3, and Histone Deacetylation , 2006, The Journal of Neuroscience.
[50] M. Valtorta,et al. Ataxin‐3 is subject to autolytic cleavage , 2006, The FEBS journal.
[51] K. Beyer. α-Synuclein structure, posttranslational modification and alternative splicing as aggregation enhancers , 2006, Acta Neuropathologica.
[52] V. Wong,et al. A multistep mutation mechanism drives the evolution of the CAG repeat at MJD/SCA3 locus , 2006, European Journal of Human Genetics.
[53] F. Hartl,et al. Proteolytic cleavage of polyglutamine-expanded ataxin-3 is critical for aggregation and sequestration of non-expanded ataxin-3. , 2006, Human molecular genetics.
[54] R. Montiel,et al. Population Genetics of Wild-Type CAG Repeats in the Machado-Joseph Disease Gene in Portugal , 2006, Human Heredity.
[55] Elena Cattaneo,et al. Progressive loss of BDNF in a mouse model of Huntington's disease and rescue by BDNF delivery. , 2005, Pharmacological research.
[56] H. Paulson,et al. Ataxin-3 suppresses polyglutamine neurodegeneration in Drosophila by a ubiquitin-associated mechanism. , 2005, Molecular cell.
[57] H. Hendriks,et al. Age at onset variance analysis in spinocerebellar ataxias: A study in a Dutch–French cohort , 2005, Annals of neurology.
[58] H. Zoghbi,et al. The Effects of the Polyglutamine Repeat Protein Ataxin-1 on the UbL-UBA Protein A1Up* , 2004, Journal of Biological Chemistry.
[59] Manuela M. Santos,et al. Genomic structure, promoter activity, and developmental expression of the mouse homologue of the Machado-Joseph disease (MJD) gene. , 2004, Genomics.
[60] Claus Lindbjerg Andersen,et al. Normalization of Real-Time Quantitative Reverse Transcription-PCR Data: A Model-Based Variance Estimation Approach to Identify Genes Suited for Normalization, Applied to Bladder and Colon Cancer Data Sets , 2004, Cancer Research.
[61] D. Wolf,et al. A genomic screen identifies Dsk2p and Rad23p as essential components of ER‐associated degradation , 2004, EMBO reports.
[62] S. Grossman,et al. A post-ubiquitination role for MDM2 and hHR23A in the p53 degradation pathway , 2004, Oncogene.
[63] P. Leigh,et al. Degradation properties of polyglutamine-expanded human androgen receptor in transfected cells , 2004, Neuroscience Letters.
[64] H. Ishimoto,et al. Molecular clearance of ataxin‐3 is regulated by a mammalian E4 , 2004, The EMBO journal.
[65] Barrington G. Burnett,et al. The polyglutamine neurodegenerative protein ataxin-3 binds polyubiquitylated proteins and has ubiquitin protease activity. , 2003, Human molecular genetics.
[66] P. Lockhart,et al. Functional association of the parkin gene promoter with idiopathic Parkinson's disease. , 2002, Human molecular genetics.
[67] A. Krainer,et al. Disruption of an SF2/ASF-dependent exonic splicing enhancer in SMN2 causes spinal muscular atrophy in the absence of SMN1 , 2002, Nature Genetics.
[68] H. Kampinga,et al. Molecular chaperones enhance the degradation of expanded polyglutamine repeat androgen receptor in a cellular model of spinal and bulbar muscular atrophy. , 2002, Human molecular genetics.
[69] G. Rouleau,et al. Improvement in the molecular diagnosis of Machado-Joseph disease. , 2001, Archives of neurology.
[70] Hangil Park,et al. Identification of proteins that interact with mammalian peptide:N-glycanase and implicate this hydrolase in the proteasome-dependent pathway for protein degradation , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[71] M. Hattori,et al. The genomic structure and expression of MJD, the Machado-Joseph disease gene , 2001, Journal of Human Genetics.
[72] Í. Lopes-Cendes,et al. Ancestral origins of the Machado-Joseph disease mutation: a worldwide haplotype study. , 2001, American journal of human genetics.
[73] C. Morris,et al. Pathology of early-onset Alzheimer's disease cases bearing the Thr113-114ins presenilin-1 mutation. , 2000, Brain : a journal of neurology.
[74] J. Hardy,et al. Aberrant splicing in the presenilin-1 intron 4 mutation causes presenile Alzheimer's disease by increased Abeta42 secretion. , 1999, Human molecular genetics.
[75] Osamu Hori,et al. A Novel Presenilin‐2 Splice Variant in Human Alzheimer's Disease Brain Tissue , 1999, Journal of neurochemistry.
[76] G. Schellenberg,et al. Missense and silent tau gene mutations cause frontotemporal dementia with parkinsonism-chromosome 17 type, by affecting multiple alternative RNA splicing regulatory elements. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[77] S. Pulst,et al. Expression of ataxin‐2 in brains from normal individuals and patients with Alzheimer's disease and spinocerebellar ataxia 2 , 1999, Annals of neurology.
[78] Í. Lopes-Cendes,et al. Study of three intragenic polymorphisms in the Machado-Joseph disease gene (MJD1) in relation to genetic instability of the (CAG)n tract , 1999, European Journal of Human Genetics.
[79] E. Hirsch,et al. Heterogeneous Intracellular Localization and Expression of Ataxin-3 , 1998, Neurobiology of Disease.
[80] T. Klockgether,et al. An Isoform of Ataxin‐3 Accumulates in the Nucleus of Neuronal Cells in Affected Brain Regions of SCA3 Patients , 1998, Brain pathology.
[81] Fumiaki Tanaka,et al. Nuclear inclusions of the androgen receptor protein in spinal and bulbar muscular atrophy , 1998, Annals of neurology.
[82] Nancy M Bonini,et al. Expanded Polyglutamine Protein Forms Nuclear Inclusions and Causes Neural Degeneration in Drosophila , 1998, Cell.
[83] A Dürr,et al. Spinocerebellar ataxia type 7 (SCA7): a neurodegenerative disorder with neuronal intranuclear inclusions. , 1998, Human molecular genetics.
[84] Dale E. Bredesen,et al. Caspase Cleavage of Gene Products Associated with Triplet Expansion Disorders Generates Truncated Fragments Containing the Polyglutamine Tract* , 1998, The Journal of Biological Chemistry.
[85] S. W. Davies,et al. Intranuclear Neuronal Inclusions in Huntington's Disease and Dentatorubral and Pallidoluysian Atrophy: Correlation between the Density of Inclusions andIT15CAG Triplet Repeat Length , 1998, Neurobiology of Disease.
[86] H. Zoghbi,et al. Ataxin-1 with an expanded glutamine tract alters nuclear matrix-associated structures , 1997, Nature.
[87] S. W. Davies,et al. Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. , 1997, Science.
[88] Masahiko Watanabe,et al. Machado–Joseph disease gene products carrying different carboxyl termini , 1997, Neuroscience Research.
[89] K. Fischbeck,et al. Intranuclear Inclusions of Expanded Polyglutamine Protein in Spinocerebellar Ataxia Type 3 , 1997, Neuron.
[90] K. Fischbeck,et al. Machado‐Joseph disease gene product is a cytoplasmic protein widely expressed in brain , 1997, Annals of neurology.
[91] L. Cupples,et al. A familial factor independent of CAG repeat length influences age at onset of Machado-Joseph disease. , 1996, American journal of human genetics.
[92] S. Narumiya,et al. Expanded polyglutamine in the Machado–Joseph disease protein induces cell death in vitro and in vivo , 1996, Nature Genetics.
[93] Alexandra Durr,et al. Spinocerebellar ataxia 3 and machado‐joseph disease: Clinical, molecular, and neuropathological features , 1996, Annals of neurology.
[94] L Junck,et al. Machado-Joseph disease and SCA3 , 1996, Neurology.
[95] Í. Lopes-Cendes,et al. Correlation between CAG repeat length and clinical features in Machado-Joseph disease. , 1995, American journal of human genetics.
[96] L. Schöls,et al. Trinucleotide expansion within the MJD1 gene presents clinically as spinocerebellar ataxia and occurs most frequently in German SCA patients. , 1995, Human molecular genetics.
[97] W. Brown,et al. Inhibition of protein synthesis separates autophagic sequestration from the delivery of lysosomal enzymes. , 1993, Journal of cell science.
[98] M. Gossen,et al. Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[99] R. A. Crowther,et al. Multiple isoforms of human microtubule-associated protein tau: sequences and localization in neurofibrillary tangles of Alzheimer's disease , 1989, Neuron.
[100] R Core Team,et al. R: A language and environment for statistical computing. , 2014 .
[101] Thomas M. Durcan,et al. The Machado-Joseph disease-associated mutant form of ataxin-3 regulates parkin ubiquitination and stability. , 2011, Human molecular genetics.
[102] Jürgen Cox,et al. A practical guide to the MaxQuant computational platform for SILAC-based quantitative proteomics , 2009, Nature Protocols.
[103] Brad T. Sherman,et al. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources , 2008, Nature Protocols.
[104] Yi Zhang,et al. Bre1, an E3 ubiquitin ligase required for recruitment and substrate selection of Rad6 at a promoter. , 2003, Molecular cell.
[105] Shigenobu Nakamura,et al. CAG expansions in a novel gene for Machado-Joseph disease at chromosome 14q32.1 , 1994, Nature Genetics.
[106] E. Fellinger,et al. Occurrence and inhibition by cycloheximide of apoptosis in vinblastine-treated murine pancreas. A role for autophagy? , 1991, Acta biologica Hungarica.
[107] T. Papadopoulos,et al. Regression of rat liver autophagic vacuoles by locally applied cycloheximide. , 1986, Laboratory investigation; a journal of technical methods and pathology.
[108] J. Kovács. Effect of cycloheximide on induced autophagy in epithelial cells of the seminal vesicle of mice. , 1974, Acta morphologica Academiae Scientiarum Hungaricae.